

TABLE OF CONTENTS

INTRODUCTION	4
SAFETY AND EFFICACY	4
Safety	4
<i>Immunogenicity</i>	4
<i>Off-Target Effects and Toxicities</i>	4
Specific Medical Indications	5
<i>Metabolic Disorders</i>	5
<i>Oncology and Targeted Drug Delivery</i>	5
<i>Cardiovascular and Neurological Diseases</i>	6
<i>Other Therapeutic Applications</i>	6
THE IMPORTANCE OF REAL-WORLD EVIDENCE	7
General	7
Big Data Approaches To RWE	7
Circles RWE Datasets	8
Physicians-Owned Circles: Maximizing RWE Quality	8

TABLE OF CONTENTS

CONCLUSION	9
Summary	9
Considerations For Specific Constituencies	9
<i>For Clinicians</i>	9
<i>For Peptide Manufacturers</i>	10
<i>For Payers (Including Employer Groups)</i>	10
<i>For AI Healthcare Models</i>	10
<i>For Medical Societies and Patient Advocacy Groups</i>	11
APPENDIX A: FDA APPROVALS OF PEPTIDE THERAPEUTICS (2016-2024)	12
APPENDIX B: SELECT PEPTIDE THERAPEUTICS AND INDICATIONS	13
APPENDIX C: ADVANTAGES OF CIRCLES OVER “BIG DATA” RWE	15
APPENDIX D: REFERENCES	19